AstraZeneca has unveiled plans to invest $50bn in the US by 2030, reinforcing the country’s position in the global medicines manufacturing and research and development sectors.
The financial commitment is projected to generate tens of thousands of skilled jobs, both directly and indirectly, across the nation.
Central to this investment is the establishment of a new multi-billion dollar manufacturing facility in Virginia.
The facility will focus on producing drug substances for AstraZeneca’s weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9, and combination small molecule products.
The centre will utilise advanced technologies such as AI, automation, and data analytics to enhance production efficiency. The latest investment follows a previous announcement of $3.5bn in November 2024.
The Virginia facility represents AstraZeneca’s largest single manufacturing investment worldwide.
In addition, the $50bn investment over the next five years will encompass several other projects. These include the expansion of the R&D facility in Gaithersburg, Maryland, and the development of a R&D centre in Kendall Square, Cambridge, Massachusetts.
The company also plans to establish next-generation manufacturing facilities for cell therapy in Rockville, Maryland, and Tarzana, California, alongside continuous manufacturing expansion in Mount Vernon, Indiana, and speciality manufacturing growth in Coppell, Texas. New sites will also be set up to support clinical trials.
The collective investments are part of AstraZeneca’s strategy to achieve $80bn in total revenue by 2030, with an anticipated 50% of this revenue expected to be generated in the US.
AstraZeneca CEO Pascal Soriot said: “Today’s announcement underpins our belief in America’s innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally. It will also support our ambition to reach $80 billion in revenue by 2030.
“I look forward to partnering with Governor Youngkin and his team to work on our largest single manufacturing investment ever.
“It reflects the Commonwealth of Virginia’s desire to create highly skilled jobs in science and technology, and will strengthen the country’s domestic supply chain for medicines.”
